Condition (MeSH)
Inflammatory Breast Neoplasms
ClinicalTrials.gov lists 112 trials for Inflammatory Breast Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
112 of the 112 trials are tagged with Inflammatory Breast Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Inflammatory Breast Neoplasms trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 6 |
| 2016 | 3 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 59 months across 77 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Inflammatory Breast Neoplasms trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 15 |
| Phase 1/2 | 9 |
| Phase 2 | 50 |
| Phase 2/3 | 3 |
| Phase 3 | 14 |
| Not applicable | 13 |
| Observational | 8 |
How many Inflammatory Breast Neoplasms trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 14 |
| Completed | 54 |
| Terminated | 17 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Inflammatory Breast Neoplasms trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 11 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| GlaxoSmithKline | 2 |
| SWOG Cancer Research Network | 2 |
Which drugs are being tested for Inflammatory Breast Neoplasms? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 36 |
| (nab)-paclitaxel | 20 |
| TRASTUZUMAB | 17 |
| PEMBROLIZUMAB | 6 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ddEpirubicin | 19 |
| Docetetaxel | 18 |
| Doxorubicine | 17 |
| or carboplatin | 15 |
| Filgrastime (G-CSF) | 11 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Inflammatory Breast Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutropenia (ANC) | 47 | 1 |
| Febrile neutropenia | 29 | 8 |
| Diarrhea | 26 | 12 |
| Neutrophil count decreased | 26 | 6 |
| Fatigue | 25 | 10 |
Showing 5 of 10 adverse events.
Which publications cover Inflammatory Breast Neoplasms? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study. | Breast cancer research : BCR | 2025 | Yes |
| TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. | Breast cancer research : BCR | 2024 | Yes |
| Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). | ESMO open | 2021 | Yes |
| PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. | Molecular cancer therapeutics | 2019 | Yes |
| 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. | The Lancet. Oncology | 2016 | Yes |
Showing 5 of 21 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Inflammatory breast cancer | Annual incidence | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.